-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, under the background of the continuous advancement of medical reform and the country's strong support for medical innovation, pharmaceutical companies have begun to passively or actively participate in the wave of transformation and upgrading
.
It is worth noting that, affected by this, more and more pharmaceutical companies have begun to introduce new drugs and innovative therapies to enrich their product pipelines and enhance their innovation competitiveness
.
Genting Xinyao introduced a new generation of BTK inhibitors.
On September 17, Genting Xinyao announced that it has cooperated with Suzhou Sinovi Pharmaceutical Technology Co.
, Ltd.
(hereinafter referred to as "Sinova") and Hong Kong China Antibody Pharmaceutical Co.
, Ltd.
") Reached an exclusive license agreement to develop, manufacture and commercialize XNW1011 (called "SN1011" by Chinese antibodies) for the treatment of kidney disease on a global scale
.
It is understood that XNW1011 is a covalent and reversible Bruton's tyrosine kinase (BTK) inhibitor
.
According to the terms of the agreement, Genting Shining will pay SinoVision and China Antibodies an advance payment of US$12 million and a total of US$549 million in future development, registration and commercialization milestone payments, as well as high single-digit global net sales.
Royalties paid in low double-digit percentages
.
In addition, the agreement also agreed to transfer all the technology of the existing manufacturing process to Yunding Xinyao to support future development and commercialization
.
Saisheng Pharmaceuticals introduced small molecule conjugate drugs on September 16, Saisheng Pharmaceuticals also announced that it has reached a cooperation and licensing agreement with Tarveda Therapeutics, and will act as the latter’s exclusive partner in the Greater China region (including Mainland China, Hong Kong, Hong Kong, China).
Macau and Taiwan) develop, produce and commercialize new small molecule conjugated drug product portfolios
.
The product portfolio consists of a combination of PI3K inhibitors and HSP90, and is currently in the preclinical research stage
.
According to the terms of the agreement, Saisheng Pharmaceutical will pay an advance payment to Tarveda and have the right to make equity investments in the latter
.
Tarveda will be eligible to receive milestone payments from Saisheng Pharmaceutical for key stages of development, approval and commercial sales, as well as royalties based on the net sales of the licensed product portfolio in Greater China
.
It is worth mentioning that this is not the first cooperation between the two parties.
In fact, in March 2020, Saisheng Pharmaceutical and Tarveda have signed an exclusive license agreement for the small molecule conjugate drug PEN-866 in Greater China
.
Conclusion In general, pharmaceutical companies are now vigorously "bringing in", in fact, they are in order to better "go out"
.
In the future, with the continuous improvement of domestic pharmaceutical companies' innovation capabilities and the continuous emergence of innovative achievements, the international participation of Chinese pharmaceutical companies will continue to upgrade
.
In this context, more and more high-quality domestic drugs will also go out to seize a larger market and benefit more patients
.
However, it should be noted that not all enterprises are suitable for the "License in" mode
.
It is not just simply buying, buying and buying, it requires the company to have a high level of technology, can understand the project, know the quality of the project, and then have the research and development ability to continue to support the subsequent product development
.
.
It is worth noting that, affected by this, more and more pharmaceutical companies have begun to introduce new drugs and innovative therapies to enrich their product pipelines and enhance their innovation competitiveness
.
Genting Xinyao introduced a new generation of BTK inhibitors.
On September 17, Genting Xinyao announced that it has cooperated with Suzhou Sinovi Pharmaceutical Technology Co.
, Ltd.
(hereinafter referred to as "Sinova") and Hong Kong China Antibody Pharmaceutical Co.
, Ltd.
") Reached an exclusive license agreement to develop, manufacture and commercialize XNW1011 (called "SN1011" by Chinese antibodies) for the treatment of kidney disease on a global scale
.
It is understood that XNW1011 is a covalent and reversible Bruton's tyrosine kinase (BTK) inhibitor
.
According to the terms of the agreement, Genting Shining will pay SinoVision and China Antibodies an advance payment of US$12 million and a total of US$549 million in future development, registration and commercialization milestone payments, as well as high single-digit global net sales.
Royalties paid in low double-digit percentages
.
In addition, the agreement also agreed to transfer all the technology of the existing manufacturing process to Yunding Xinyao to support future development and commercialization
.
Saisheng Pharmaceuticals introduced small molecule conjugate drugs on September 16, Saisheng Pharmaceuticals also announced that it has reached a cooperation and licensing agreement with Tarveda Therapeutics, and will act as the latter’s exclusive partner in the Greater China region (including Mainland China, Hong Kong, Hong Kong, China).
Macau and Taiwan) develop, produce and commercialize new small molecule conjugated drug product portfolios
.
The product portfolio consists of a combination of PI3K inhibitors and HSP90, and is currently in the preclinical research stage
.
According to the terms of the agreement, Saisheng Pharmaceutical will pay an advance payment to Tarveda and have the right to make equity investments in the latter
.
Tarveda will be eligible to receive milestone payments from Saisheng Pharmaceutical for key stages of development, approval and commercial sales, as well as royalties based on the net sales of the licensed product portfolio in Greater China
.
It is worth mentioning that this is not the first cooperation between the two parties.
In fact, in March 2020, Saisheng Pharmaceutical and Tarveda have signed an exclusive license agreement for the small molecule conjugate drug PEN-866 in Greater China
.
Conclusion In general, pharmaceutical companies are now vigorously "bringing in", in fact, they are in order to better "go out"
.
In the future, with the continuous improvement of domestic pharmaceutical companies' innovation capabilities and the continuous emergence of innovative achievements, the international participation of Chinese pharmaceutical companies will continue to upgrade
.
In this context, more and more high-quality domestic drugs will also go out to seize a larger market and benefit more patients
.
However, it should be noted that not all enterprises are suitable for the "License in" mode
.
It is not just simply buying, buying and buying, it requires the company to have a high level of technology, can understand the project, know the quality of the project, and then have the research and development ability to continue to support the subsequent product development
.
